Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by 2Xideas AG

2Xideas AG lowered its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 16.1% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 14,472 shares of the medical equipment provider’s stock after selling 2,778 shares during the period. 2Xideas AG’s holdings in Intuitive Surgical were worth $7,554,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Atala Financial Inc acquired a new position in Intuitive Surgical during the 4th quarter worth $25,000. Berbice Capital Management LLC acquired a new position in Intuitive Surgical during the 4th quarter valued at about $26,000. BankPlus Trust Department acquired a new stake in shares of Intuitive Surgical in the 4th quarter worth approximately $28,000. Hurley Capital LLC bought a new position in shares of Intuitive Surgical in the fourth quarter valued at approximately $28,000. Finally, Summit Securities Group LLC acquired a new position in shares of Intuitive Surgical during the fourth quarter valued at approximately $30,000. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of ISRG opened at $451.58 on Friday. The company has a 50-day simple moving average of $545.18 and a 200-day simple moving average of $532.64. Intuitive Surgical, Inc. has a 52 week low of $364.17 and a 52 week high of $616.00. The firm has a market capitalization of $160.84 billion, a P/E ratio of 70.45, a P/E/G ratio of 5.85 and a beta of 1.55.

Wall Street Analyst Weigh In

ISRG has been the subject of a number of research analyst reports. Barclays upped their price target on shares of Intuitive Surgical from $610.00 to $674.00 in a report on Monday, January 27th. Robert W. Baird lowered their price objective on shares of Intuitive Surgical from $707.00 to $600.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 18th. Bernstein Bank upped their price objective on shares of Intuitive Surgical from $655.00 to $700.00 and gave the company an “overweight” rating in a research note on Monday, January 27th. Raymond James raised their price objective on shares of Intuitive Surgical from $560.00 to $688.00 and gave the company an “outperform” rating in a research report on Friday, January 24th. Finally, Royal Bank of Canada increased their price target on shares of Intuitive Surgical from $611.00 to $641.00 in a research note on Monday, January 27th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and an average price target of $611.86.

Insider Activity at Intuitive Surgical

In other news, Director Amal M. Johnson sold 4,635 shares of the stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total value of $2,626,191.00. Following the completion of the transaction, the director now owns 12,275 shares in the company, valued at approximately $6,955,015. This represents a 27.41 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Jamie Samath sold 94 shares of Intuitive Surgical stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $571.11, for a total transaction of $53,684.34. Following the sale, the chief financial officer now owns 2,630 shares in the company, valued at approximately $1,502,019.30. This trade represents a 3.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 33,754 shares of company stock worth $17,691,621 over the last three months. Company insiders own 0.70% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.